Skip to main content
. Author manuscript; available in PMC: 2023 Jan 1.
Published in final edited form as: J Periodontal Res. 2021 Nov 8;57(1):173–185. doi: 10.1111/jre.12951

Table 3.

The effect of imipramine (IMP) on ceramide (CER) content in macrophages treated with LPS, PA or LPS plus PA

Treatment IMP C16-CER C18-CER C20-CER C22-CER C24-CER C24:1-CER Total CER
Control − IMP 0.74±0.11 0.05±0.01 0.03±0.01 0.36±0.05 2.24±0.32 1.44±0.21 5.00±0.72¶,
+ IMP 0.96±0.14 0.13±0.02 0.04±0.01 0.46±0.07 1.69±0.24 1.41±0.20 4.85±0.69
LPS − IMP 1.16±0.17 0.06±0.01 0.03±0.01 0.34±0.05 2.21±0.32 1.52±0.22 5.51±0.79#
+ IMP 1.33±0.19 0.11±0.02 0.05±0.01 0.43±0.06 2.00±0.29 1.22±0.18 5.31±0.76
PA − IMP 1.52±0.22 0.28±0.04 0.17±0.03 1.54±0.22 1.98±0.28 1.32±0.19 7.00±1.00
+ IMP 2.08±0.30 0.46±0.07 0.23±0.03 1.61±0.23 1.57±0.23 0.76±0.11 6.83±0.98^
LPS+PA − IMP 4.84±0.69 1.23±0.18 0.66±0.10 3.56±0.51 3.37±0.48 2.72±0.39 17.00±2.43*
+ IMP 3.08±0.44 0.62±0.09 0.28±0.04 1.94±0.28 1.88±0.27 1.16±0.17 9.19±1.31+

Raw264.7 cells were treated with 1 ng/ml of LPS, 100 μM of PA or both LPS and PA in the presence or absence of 50 μM of IMP for 12 h. After treatment, cells were harvested and subjected to the lipidomic analysis of CERs as described in Methods. The unit of the values is pmol/nmol Pi. IMP, imipramine; CER, ceramide; PA, palmitic acid.

*

p<0.01 vs +, ¶, # or ^.